Stuart Scott's ESPY Acceptance Speech

On Wednesday 16 July 2014, ESPN's ESPY Awards aired.

This year, the Jimmy V. Perseverance Award was given to longtime ESPN anchor Stuart Scott, who has been battling cancer for the past seven years.

His acceptance speech is honest and moving and definitely worth watching.

Note: Scott was diagnosed in 2007 with appendiceal cancer, or cancer of the appendix. It was found when he underwent surgery for appendicitis. It is an understatement to say that his cancer is rare.

However, appendiceal cancer falls under the umbrella of gastrointestinal carcinoid tumors. There are foregut tumors, midgut tumors, and hindgut tumors, with midgut tumors-- and notably, where appendiceal cancer falls-- being the most common of the three anatomical locations.

Gastrointestinal carcinoid tumors like appendiceal cancer are considered indolent cancers. They grow slowly. In fact, often when cancer is found in the appendix it has a benign clinical course and does not metastasize, or spread.

At least two molecular tumor markers, found in high concentrations, have been associated with poor outcomes in these tumors. Otherwise, determining prognosis in patients with these carcinoid tumors is extremely difficult.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap